Clinical trials
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastric cancer or gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 1,144 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
Tucson, ArizonaAges 18 years+ - NCT06932068RecruitingPhase 2
Study of new drug combo for advanced stomach cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
Zhengzhou, HenanAges 18–75 - NCT06081647Recruiting
Testing a new airway device for endoscopy
This trial tests a special mouth-and-throat device designed to help you breathe easier during a routine endoscopy or colonoscopy. If you are a generally healthy adult scheduled for one of these procedures, you may be able to join.
Nanjing, JiangsuAges 18–60 - NCT06873659RecruitingPhase 1
Testing SON-DP for advanced solid tumors
This trial tests a new drug called SON-DP for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06796764Recruiting
Breathing tube safety during endoscopy in people with obesity
This trial tests a special breathing tube to see if it can prevent low oxygen levels during sedated endoscopy in people with obesity. If you are scheduled for both an upper endoscopy and colonoscopy, this study may help make the procedure safer.
Hangzhou, ZhejiangAges 18–70 - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Birmingham, AlabamaAges 18 years+ - NCT06222645Recruiting
Comparing two dyes in gastrointestinal surgery
This trial compares two dyes used during stomach or intestine surgery to see which helps surgeons see the blood flow better. It may help decide which dye works best for safe reconnections.
Yantai, ShandongAges 18 years+ - NCT06134960RecruitingPhase 1
KD-496 CAR T-cells for advanced solid tumors with NKG2DL or CLDN18.2
This trial tests a new type of immune cell therapy called KD-496, which is a CAR T-cell designed to attack tumors that have NKG2DL or CLDN18.2 markers. It may be an option for people with advanced solid tumors (commonly stomach or pancreatic cancer) who have tried at least two prior treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06071507Recruiting
Comparing treatments for stomach blockage in pancreatic cancer
This trial compares three ways to relieve a stomach or duodenal blockage caused by pancreatic cancer: placing a stent, performing a bypass with a thin tube (endoscopy), or surgical bypass. It aims to find which option helps patients eat and feel better sooner.
ParisAges 18 years+ - NCT06055439RecruitingPhase 1/Phase 2
CAR T cell therapy for GI cancers
This trial tests a new type of immunotherapy called CAR T cells that target a protein (CDH17) found on certain stomach, colon, and rectal cancers. It's designed for people whose cancer has spread and has been treated before.
Atlanta, GeorgiaAges 18–85 - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05593458RecruitingPhase 3
Stomach cancer surgery before chemo: artery-based or drip chemo
This trial compares two ways of giving chemotherapy before surgery for locally advanced stomach or stomach–esophagus cancer: chemo sent through an artery versus chemo given through an IV line. It also studies adding PD-1 immunotherapy to see which approach works better and is safer.
Hangzhou, ZhejiangAges 18–75 - NCT04214119Recruiting
Capsule test during endoscopy to find early esophageal cancer
This trial studies an “EsophaCap” capsule that can be swallowed during an endoscopy to help detect early esophageal cancer. It may help find cancer earlier and guide next steps, if your results are concerning.
Baltimore, MarylandAges 18 years+ - NCT05332002RecruitingPhase 2
Study chemotherapy plus immunotherapy for HER2-negative esophageal cancer
This Phase 2 trial tests a combination treatment called sFOLFOXIRI for advanced esophageal or stomach-area cancer that is HER2-negative. It aims to see how well the treatment works and whether it is safe for people who have not had standard chemotherapy for this metastatic cancer yet.
Hamilton, New JerseyAges 18 years+ - NCT05226169RecruitingPhase 3
Iron medicine plus standard therapy for advanced stomach cancer
This Phase 3 study tests whether giving ferric carboxymaltose (an IV iron treatment) helps people with advanced stomach or stomach–esophagus cancer and iron-deficiency anemia. The goal is to improve safety and how well the standard first-line cancer treatment works.
SeoulAges 19 years+ - NCT04949737Recruiting
Study stomach bacteria and stomach cancer in Martinique adults
This study looks at how common Helicobacter pylori (a common stomach germ) is in adults with stomach cancer in Martinique, and how it relates to stomach cancer. It mainly involves answering questionnaires and allowing study details to be collected to better understand risk and patterns.
Fort-de-FranceAges 18 years+ - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80 - NCT04306458Recruiting
Testing robot-assisted vs standard surgery for resectable esophageal cancer
This trial compares a robot-assisted approach to a standard minimally invasive approach for surgery in people with certain types of esophageal or gastroesophageal junction cancer that can be removed. It aims to see which surgery method works better and is safer for these patients.
MainzAges 18–90 - NCT05563012RecruitingPhase 2
Short radiation plus chemo and PD-1 immunotherapy for stomach cancer
This Phase 2 trial tests whether giving a short course of radiation before surgery, along with chemotherapy and a PD-1 immunotherapy drug, can improve treatment outcomes for locally advanced stomach cancer. It may help shrink the tumor before surgery and strengthen the immune system’s attack on cancer.
Wuhan, HubeiAges 18–75 - NCT05813015RecruitingPhase 3
Testing S-1 after stomach cancer surgery with or without sequence therapy
This Phase 3 study compares two ways of giving S-1 medicine after curative stomach cancer surgery in stage III disease. It aims to see whether the sequential approach improves outcomes while keeping treatment safe.
Hanzhou, ZhejiangAges 18–75 - NCT05640609RecruitingPhase 1/Phase 2
Stomach cancer study using chemo plus immunotherapy plus targeted drug
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
ChengduAges 18–70 - NCT05561504Recruiting
Study of stomach bacteria resistance in adults
This study looks at how common a stomach bacteria infection is and which antibiotics still work. You may help researchers by providing consent for related study participation and sample tracking.
MunichAges 18 years+ - NCT06275204Recruiting
H. pylori test and treat study for young adults
This study tests and treats young adults for H. pylori, a stomach bacteria, to see if treating it reduces future health risks. If you haven't been treated for H. pylori before, you may join.
Zagreb, City of ZagrebAges 30–34 - NCT06023758RecruitingPhase 2
Study of two drugs with or without chemo for HER2-positive stomach cancer
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric cancer or gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 1,144 recruiting gastric cancer or gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal-junction Cancer
- Metastatic Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.